Maprotiline

Brain Tumor

University of RochesterSmall moleculePhase 1Active

CC

41/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 81/ 100

Competitive context

61 Active assets in the Brain Tumor cohort.

Asset / Sponsor	Phase	Rating
Cediranib M.D. Anderson Cancer Center	Phase 2	BBB
Temsirolimus M.D. Anderson Cancer Center	Phase 2	BBB
Sorafenib National Cancer Institute (NCI)	Phase 2	BB
Bxcl501 Kaohsiung Medical University Chung-Ho Memorial Hospital	Phase 4	BB
Nivolumab InSightec	Phase 3	BB

View all 50 →

Same molecule, other indications

Maprotiline is also rated in:

physiological malfunction arising from mental factorDormant

B

Indicative ·

57 / 100

anxiety disorderDormant

B

Indicative ·

57 / 100

dementiaDormant

CCC

Indicative ·

55 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.